Obesity and lung cancer research shows mixed results; experts urge moving beyond BMI to waist metrics and CT-based body ...

Merieme Klobocista, MD, of Hackensack Meridian Health explains how molecular testing is personalizing treatment for ovarian ...

Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for ...

Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU ...

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...

The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in ...

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Five phase 3 analyses presented as late-breaking abstracts at the 2026 European Society for Medical Oncology (ESMO) Congress ...

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders ...

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.